ACGN
Price:
$0.3849
Market Cap:
$3.24M
Aceragen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare pulmonary and rheumatic diseases in the United States. Its clinical development pipeline includes ACG-701, which is in Phase 2 clinical trial for cystic fibrosis pulmonary exacerbations, as well as for melioidosis; and ACG-801 for farber disease. Aceragen, Inc. has a collaboration and option agreement with Scriptr Global, Inc. to identify, research, and develop gene therapy candidates for the treatment, palliation, diagnosis, or prevention of myotonic dystrophy type 1 and Friedreich's Ataxia. The company was formerly known as Idera Pharmaceuticals, Inc. a...[Read more]
Industry
Biotechnology
IPO Date
1996-01-25
Stock Exchange
NASDAQ
Ticker
ACGN
According to Aceragen, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -8243034.00. This represents a change of 91.62% compared to the average of -4301658.48 of the last 4 quarters.
The mean historical Enterprise Value of Aceragen, Inc. over the last ten years is 131.09M. The current -8243034.00 Enterprise Value has changed -728.80% with respect to the historical average. Over the past ten years (40 quarters), ACGN's Enterprise Value was at its highest in in the June 2015 quarter at 402.30M. The Enterprise Value was at its lowest in in the December 2017 quarter at -112420000.00.
Average
131.09M
Median
101.54M
Minimum
-3730137.95
Maximum
346.17M
Discovering the peaks and valleys of Aceragen, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.12%
Maximum Annual Enterprise Value = 346.17M
Minimum Annual Increase = -311.65%
Minimum Annual Enterprise Value = -3730137.95
Year | Enterprise Value | Change |
---|---|---|
2022 | 7.89M | -311.65% |
2021 | -3730137.95 | -104.06% |
2020 | 91.84M | 606.76% |
2019 | 12.99M | 476.59% |
2018 | 2.25M | -99.04% |
2017 | 235.43M | 111.66% |
2016 | 111.23M | -66.27% |
2015 | 329.81M | -4.72% |
2014 | 346.17M | 95.57% |
2013 | 177.01M | 1.12% |
The current Enterprise Value of Aceragen, Inc. (ACGN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
32.00M
5-year avg
22.25M
10-year avg
131.09M
Aceragen, Inc.’s Enterprise Value is less than Addex Therapeutics Ltd (6.58M), less than ERYTECH Pharma S.A. (20.24M), less than Soligenix, Inc. (669.24K), less than Avenue Therapeutics, Inc. (1.25M), less than Akari Therapeutics, Plc (17.47M), less than Armata Pharmaceuticals, Inc. (138.55M), less than Anebulo Pharmaceuticals, Inc. (36.46M), less than Scopus BioPharma Inc. (-111950.00), less than Processa Pharmaceuticals, Inc. (15.28K), less than Neoleukin Therapeutics, Inc. (-6333315.00), less than Senti Biosciences, Inc. (34.09M), less than Hillstream BioPharma, Inc. (1.48M), less than SAB Biotherapeutics, Inc. (24.24M), less than Quoin Pharmaceuticals, Ltd. (-162664.00), less than Cocrystal Pharma, Inc. (11.24M), less than iBio, Inc. (17.35M), less than Bio-Path Holdings, Inc. (3.00M), less than Tempest Therapeutics, Inc. (35.14M), less than RenovoRx, Inc. (21.40M), less than Acrivon Therapeutics, Inc. Common Stock (163.47M), less than Acurx Pharmaceuticals, Inc. (17.04M),
Company | Enterprise Value | Market cap |
---|---|---|
6.58M | $11.57M | |
20.24M | $47.38M | |
669.24K | $8.31M | |
1.25M | $3.84M | |
17.47M | $18.72M | |
138.55M | $81.41M | |
36.46M | $37.86M | |
-111950.00 | $12.63K | |
15.28K | $2.81M | |
-6333315.00 | $8.20M | |
34.09M | $9.96M | |
1.48M | $4.17M | |
24.24M | $28.89M | |
-162664.00 | $2.95M | |
11.24M | $22.38M | |
17.35M | $24.15M | |
3.00M | $3.53M | |
35.14M | $39.52M | |
21.40M | $30.96M | |
163.47M | $202.87M | |
17.04M | $22.80M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aceragen, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aceragen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Aceragen, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Aceragen, Inc. (ACGN)?
What is the 3-year average Enterprise Value for Aceragen, Inc. (ACGN)?
What is the 5-year average Enterprise Value for Aceragen, Inc. (ACGN)?
How does the current Enterprise Value for Aceragen, Inc. (ACGN) compare to its historical average?